Login
Home
Charts
Search
Watchlist
Products

Privi Speciality Chemicals Ltd

PRIVISCL·NSE
3,457.90-1.63%Wed, 23 Sept '26 13:32

Privi Speciality Chemicals Ltd

PRIVISCL
NSE
3,457.90
-1.63%
|Wed, 23 Sept '26 13:32
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
13,555Cr
Close
Close Price
3,470.10
Industry
Industry
Speciality Chemicals
PE
Price To Earnings
38.75
PS
Price To Sales
5.07
Revenue
Revenue
2,671Cr
Rev Gr TTM
Revenue Growth TTM
21.63%
PAT Gr TTM
PAT Growth TTM
62.21%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
455404484464533491614559679605722666
Growth YoY
Revenue Growth YoY%
13.7-3.821.513.517.021.626.720.427.423.217.619.2
Expenses
ExpensesCr
366314393370423378481427497453541514
Operating Profit
Operating ProfitCr
89909194110113133132182151180152
OPM
OPM%
19.622.318.820.320.723.021.623.626.825.025.022.9
Other Income
Other IncomeCr
76834215907415
Interest Expense
Interest ExpenseCr
252425222222232421191817
Depreciation
DepreciationCr
313230323232353636363637
PBT
PBTCr
4039444361619081125104130113
Tax
TaxCr
101012111616262435293631
PAT
PATCr
302932314544645890759483
Growth YoY
PAT Growth YoY%
280.4403.9315.2598.948.154.6100.883.0101.268.347.143.9
NPM
NPM%
6.77.16.66.88.49.110.410.313.312.413.012.4
EPS
EPS
7.87.48.28.111.411.417.015.824.020.024.021.6
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
455404484464533491614559679605722666
Growth YoY
Revenue Growth YoY%
13.7-3.821.513.517.021.626.720.427.423.217.619.2
Expenses
ExpensesCr
366314393370423378481427497453541514
Operating Profit
Operating ProfitCr
89909194110113133132182151180152
OPM
OPM%
19.622.318.820.320.723.021.623.626.825.025.022.9
Other Income
Other IncomeCr
76834215907415
Interest Expense
Interest ExpenseCr
252425222222232421191817
Depreciation
DepreciationCr
313230323232353636363637
PBT
PBTCr
4039444361619081125104130113
Tax
TaxCr
101012111616262435293631
PAT
PATCr
302932314544645890759483
Growth YoY
PAT Growth YoY%
280.4403.9315.2598.948.154.6100.883.0101.268.347.143.9
NPM
NPM%
6.77.16.66.88.49.110.410.313.312.413.012.4
EPS
EPS
7.87.48.28.111.411.417.015.824.020.024.021.6

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
5971,0241,3411,6311,2771,4041,6081,7522,1012,5642,671
Growth
Revenue Growth%
71.530.921.6-21.710.014.59.019.922.021.6
Expenses
ExpensesCr
5288941,1281,3631,0691,2101,4221,4271,6481,9172,005
Operating Profit
Operating ProfitCr
69130213268208194186325454646666
OPM
OPM%
11.612.715.916.416.313.811.618.621.625.224.9
Other Income
Other IncomeCr
1016156743382126211926
Interest Expense
Interest ExpenseCr
1724294121246898888275
Depreciation
DepreciationCr
274347637175108123132144145
PBT
PBTCr
367915223115813331130255440472
Tax
TaxCr
82657554135103470123130
PAT
PATCr
275394176117972195185317342
Growth
PAT Growth%
96.776.787.1-33.7-16.7-78.2348.593.671.462.2
NPM
NPM%
4.55.27.010.89.26.91.35.58.812.312.8
EPS
EPS
6.810.518.628.829.924.95.524.447.983.889.6
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
5971,0241,3411,6311,2771,4041,6081,7522,1012,5642,671
Growth
Revenue Growth%
71.530.921.6-21.710.014.59.019.922.021.6
Expenses
ExpensesCr
5288941,1281,3631,0691,2101,4221,4271,6481,9172,005
Operating Profit
Operating ProfitCr
69130213268208194186325454646666
OPM
OPM%
11.612.715.916.416.313.811.618.621.625.224.9
Other Income
Other IncomeCr
1016156743382126211926
Interest Expense
Interest ExpenseCr
1724294121246898888275
Depreciation
DepreciationCr
274347637175108123132144145
PBT
PBTCr
367915223115813331130255440472
Tax
TaxCr
82657554135103470123130
PAT
PATCr
275394176117972195185317342
Growth
PAT Growth%
96.776.787.1-33.7-16.7-78.2348.593.671.462.2
NPM
NPM%
4.55.27.010.89.26.91.35.58.812.312.8
EPS
EPS
6.810.518.628.829.924.95.524.447.983.889.6

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
38383939393939393939
Reserves
ReservesCr
4054495377026837737908851,0641,373
Current Liabilities
Current LiabilitiesCr
4034576305764549291,1018961,1031,093
Non Current Liabilities
Non Current LiabilitiesCr
91107220287364428454505569637
Total Liabilities
Total LiabilitiesCr
9391,0531,4261,6041,5402,1762,3912,3432,7913,170
Current Assets
Current AssetsCr
4855418018057001,0531,2021,1421,3631,596
Non Current Assets
Non Current AssetsCr
4545126257998401,1231,1891,2011,4271,574
Total Assets
Total AssetsCr
9391,0531,4261,6041,5402,1762,3912,3432,7913,170
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
38383939393939393939
Reserves
ReservesCr
4054495377026837737908851,0641,373
Current Liabilities
Current LiabilitiesCr
4034576305764549291,1018961,1031,093
Non Current Liabilities
Non Current LiabilitiesCr
91107220287364428454505569637
Total Liabilities
Total LiabilitiesCr
9391,0531,4261,6041,5402,1762,3912,3432,7913,170
Current Assets
Current AssetsCr
4855418018057001,0531,2021,1421,3631,596
Non Current Assets
Non Current AssetsCr
4545126257998401,1231,1891,2011,4271,574
Total Assets
Total AssetsCr
9391,0531,4261,6041,5402,1762,3912,3432,7913,170

Cash Flow

Consolidated
Standalone
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
1710721247172549354281550
Investing Cash Flow
Investing Cash FlowCr
-67-81-139-206-242-320-133-180-294-358
Financing Cash Flow
Financing Cash FlowCr
-89-2012227033372-17139-198
Net Cash Flow
Net Cash FlowCr
-1405468-6917-12426-6
Free Cash Flow
Free Cash FlowCr
171074637-71-304-91212-17230
CFO To PAT
CFO To PAT%
61.1199.822.2140.2147.24.9229.2371.5152.2173.7
CFO To EBITDA
CFO To EBITDA%
24.081.99.892.382.92.426.2109.162.085.1
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
1710721247172549354281550
Investing Cash Flow
Investing Cash FlowCr
-67-81-139-206-242-320-133-180-294-358
Financing Cash Flow
Financing Cash FlowCr
-89-2012227033372-17139-198
Net Cash Flow
Net Cash FlowCr
-1405468-6917-12426-6
Free Cash Flow
Free Cash FlowCr
171074637-71-304-91212-17230
CFO To PAT
CFO To PAT%
61.1199.822.2140.2147.24.9229.2371.5152.2173.7
CFO To EBITDA
CFO To EBITDA%
24.081.99.892.382.92.426.2109.162.085.1

Ratios

Consolidated
Standalone
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
2,0601,4181,8101,6313,3137,3384,1043,8706,66911,31213,555
Price To Earnings
Price To Earnings
76.026.619.29.328.375.3184.740.835.734.538.8
Price To Sales
Price To Sales
3.51.41.41.02.65.22.52.23.24.45.1
Price To Book
Price To Book
4.72.93.12.24.69.05.04.26.08.09.6
EV To EBITDA
EV To EBITDA
33.512.910.67.818.342.527.814.917.119.022.1
Profitability Ratios
Profitability Ratios
GPM
GPM%
22.622.726.327.230.529.126.430.434.938.138.1
OPM
OPM%
11.612.715.916.416.313.811.618.621.625.224.9
NPM
NPM%
4.55.27.010.89.26.91.35.58.812.312.8
ROCE
ROCE%
7.313.217.421.114.79.05.211.815.221.421.4
ROE
ROE%
6.111.016.423.816.212.02.610.316.722.422.4
ROA
ROA%
2.95.16.611.07.64.50.94.16.610.010.0
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
2,0601,4181,8101,6313,3137,3384,1043,8706,66911,31213,555
Price To Earnings
Price To Earnings
76.026.619.29.328.375.3184.740.835.734.538.8
Price To Sales
Price To Sales
3.51.41.41.02.65.22.52.23.24.45.1
Price To Book
Price To Book
4.72.93.12.24.69.05.04.26.08.09.6
EV To EBITDA
EV To EBITDA
33.512.910.67.818.342.527.814.917.119.022.1
Profitability Ratios
Profitability Ratios
GPM
GPM%
22.622.726.327.230.529.126.430.434.938.138.1
OPM
OPM%
11.612.715.916.416.313.811.618.621.625.224.9
NPM
NPM%
4.55.27.010.89.26.91.35.58.812.312.8
ROCE
ROCE%
7.313.217.421.114.79.05.211.815.221.421.4
ROE
ROE%
6.111.016.423.816.212.02.610.316.722.422.4
ROA
ROA%
2.95.16.611.07.64.50.94.16.610.010.0
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Privi Speciality Chemicals is the world’s largest processor of a waste product from paper mills, turning it into the ingredients that make perfumes, soaps and detergents smell the way they do. It began in 1992 with two products and, after a defining move in 2012 to secure its own raw material supply, has grown into India’s largest exporter of aroma chemicals, supplying all of the world’s top 15 fragrance houses from a single, giant factory complex. The recurring approach is a “waste to value” philosophy: take a cheap, unwanted byproduct that few others can handle, apply proprietary in-house chemistry, and sell the resulting high-value molecules to the world’s biggest brands. # Business segments Three engines built on a single chemistry platform - a foundational pine-chemicals business that generates the cash, a specialty-musk business that moves up the value chain, and a dedicated joint venture that makes exclusive ingredients for the industry’s biggest buyer. ## 1. Pine-based aroma chemicals: the cash engine built on paper-mill waste **The company takes a sulphate-laden waste from pulp mills that almost no one else can process, and converts it into the world’s most widely used fragrance ingredients, giving it a structural cost advantage over competitors who use a more expensive tree-sap alternative.** - **Cheaper raw material by design** - it uses Crude Sulphate Turpentine (CST), a waste byproduct from 70+ mills across EU & NA, which costs roughly 15-20% less than the Gum Turpentine Oil (GTO) that rivals depend on. - **Dominant in the products that matter** - it holds a market-leading share of over 20% in ten products globally, including its flagship molecules Dihydromyrcenol and Amber Fleur, and those ten products alone generate 80% of the company’s revenue. - **Nothing is wasted** - side streams from making the main products are converted into additional value-added chemicals like 1,8 Cineol and Limonene, which earn better margins and follow the same “waste to wealth” logic. - **Scaling the core** - total production capacity across all product lines is 48,000 metric tons per year, with a first phase of expansion underway to take it to 54,000, and a second multi-speciality project already in progress. ## 2. Musk and specialty aroma chemicals: moving up the perfume pyramid **Using the same cheap feedstock platform, this segment makes complex, high-value molecules for premium perfumes and cosmetics - products where the company is often only the third manufacturer in the world.** - **From liquids to powders** - the segment includes Prionyl, the company’s first solid aroma chemical, used in very high-end cosmetic brands; Privi is only the third manufacturer globally to produce it. - **Built on the parent engine’s leftovers** - many of these specialty products are manufactured from side streams generated during the production of the flagship pine-based chemicals, again turning waste into higher-value output. - **A pipeline in the lab** - products under development at pilot or lab scale include Menthol, Peppermint oil, and Helvotalite, an alicyclic musk, extending the segment’s reach further into high-value fragrance and flavour territory. ## 3. PRIGIV: a dedicated factory for the world’s largest fragrance buyer **This is a 51:49 joint venture with Givaudan, the biggest flavour and fragrance company on earth, built to manufacture over 40 exclusive specialty ingredients that Givaudan has committed to buying.** - **A captive customer from day one** - the greenfield facility in Mahad was built specifically to make 42 small-volume, high-complexity fragrance ingredients exclusively for Givaudan’s high-end product line, with production starting in February 2025. - **Funded by the partner** - the ₹178 crore facility was built with equity from both partners, and the JV also carries a non-interest-bearing trade advance of roughly ₹180 crore from Givaudan to keep debt costs low. - **Just turned the corner** - the venture reported its first profitable quarter in early 2026, with a progressive ramp-up of production targeted over the next two to three years. - **Room to grow** - an additional ₹50 crore expansion is already being funded by both partners in the same 51:49 ratio, and a neighbouring 5-acre plot has been acquired for future growth beyond the original 4-acre site. # Research, development and the “waste to value” engine **A 114-person team of scientists and microbiologists working across two dedicated R&D centres translates ideas from lab scale to full commercial production entirely in-house, and is the source of every proprietary process that gives the company its cost edge.** - **Proprietary green chemistry** - the company has developed its own effluent-free processes, a continuous reaction system for its biggest products, and the critical sulphur-separation technology for CST that underpins the entire pine-based business. - **The next frontier is biowaste** - through a “Biorefinery” initiative and a dedicated biotech subsidiary, the company is converting agricultural waste into specialty chemicals using natural fermentation, and has developed enzymatic cracking of non-edible oils at R&D scale. # Group structure and partners **The company is consolidating a promoter-led ecosystem of related chemical entities into a single listed platform, while anchoring its renewable-energy supply through captive solar investments.** - **Simplification in progress** - a scheme of amalgamation is underway to merge Privi Fine Sciences (a promoter-controlled entity making specialty aroma chemicals and green-science products from corn cobs and vegetable oil) and Privi Biotechnologies (a wholly owned biotech subsidiary) into the listed parent, with final approval expected during FY27. - **Captive solar to cut power costs** - the company holds a 26% stake in a 10 MW solar plant and recently took a 26% stake in a second solar facility, both in Maharashtra, to become a captive user and reduce its dependence on coal and natural gas. - **Global reach from one site** - exports contribute roughly 70% of revenue, served by seven distribution centres across Europe, the Americas and Asia, and three stocking points in India, reaching customers in more than 40 countries.

Documents — Privi Speciality Chemicals Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/7m6dy4a5wrzugn6g9ezi1tjy.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/0unrguv8o6t7zpg0hzjg04o5.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/bznbslifrohvylt3yd96oxp5.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/n5vqtax03mvwg59x2p0v0p8v.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/qwv73j4ik8s2w95wfovwpwit.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/mnw4mqpse1lneau38dt2i1ug.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/ecoqjdtiswemdqb85wp2jlw5.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/17v9r35ceitggctp3y2xn0fz.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/07i1pxasqils0tu2qbyjgzjd.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/zipjmwfcwvi7f7ufjr8k29h3.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/8a7gdu37ylq22dmsc476i3p5.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/7386gon3oh62bytdjbxwbzzh.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/t9peo7xqulb8kvm3l45ip9vq.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/btay29jvi6otg9nk38fsaai2.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/mbg2bgqao1n9lb9yiqu7q4oe.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/q6793p7ke5c1muafw5v5e8hf.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/rad75k9cekmcmweklg5gc5tt.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/dhqj3hojqt3cp4zilfs02r2k.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/tpepzdp0idtk9zgv5k1cz3pv.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/2weuadydovd6g58h38s3z6rz.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/aykn9jqmzv9jib7avkmzoz4v.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/djk487tebm37n7tn569bp0a5.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/dztrltqj7gbobkcrwjb0rra0.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/pcukbwkmq01r21brnbvp4eqq.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/rkdp1b1m6pd2yf8ychvnwv9b.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/yfn92dp46xmojn7l2ka3ctk8.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/lddah86iucr74k3r167myxmd.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/3u3t7yyz3ccs7g3489hlo1ai.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/c0pzvwbcrfhermthkegp8jxr.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/3vgdt5fuo7692lgmla7oaniy.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/d8w36vc7ewdlhprwir7vrq8q.pdf

Concall Transcript Summaries — Privi Speciality Chemicals Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3APRIVISCL/transcript-notes/202606/7m6dy4a5wrzugn6g9ezi1tjy.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3APRIVISCL/transcript-notes/202603/0unrguv8o6t7zpg0hzjg04o5.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3APRIVISCL/transcript-notes/202512/bznbslifrohvylt3yd96oxp5.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3APRIVISCL/transcript-notes/202509/n5vqtax03mvwg59x2p0v0p8v.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3APRIVISCL/transcript-notes/202506/qwv73j4ik8s2w95wfovwpwit.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3APRIVISCL/transcript-notes/202503/mnw4mqpse1lneau38dt2i1ug.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3APRIVISCL/transcript-notes/202412/ecoqjdtiswemdqb85wp2jlw5.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3APRIVISCL/transcript-notes/202409/17v9r35ceitggctp3y2xn0fz.pdf